Atyr PHARMA (NASDAQ:ATYR) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of Atyr PHARMA (NASDAQ:ATYR) in a research report released on Monday, Marketbeat Ratings reports. The brokerage issued an overweight rating on the stock.

ATYR has been the subject of several other reports. HC Wainwright restated a “buy” rating and set a $35.00 target price on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Wells Fargo & Company assumed coverage on Atyr PHARMA in a research note on Friday, October 4th. They set an “overweight” rating and a $17.00 target price for the company. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $19.25.

Atyr PHARMA Price Performance

NASDAQ:ATYR opened at $3.74 on Monday. The firm has a 50-day moving average of $3.34. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. Atyr PHARMA has a 12 month low of $1.39 and a 12 month high of $4.22. The stock has a market capitalization of $313.94 million, a price-to-earnings ratio of -3.98 and a beta of 1.08.

Atyr PHARMA (NASDAQ:ATYR) last announced its earnings results on Thursday, November 7th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). Equities analysts anticipate that Atyr PHARMA will post -0.89 EPS for the current year.

Hedge Funds Weigh In On Atyr PHARMA

A hedge fund recently raised its stake in Atyr PHARMA stock. JPMorgan Chase & Co. increased its position in Atyr PHARMA INC (NASDAQ:ATYR) by 52.0% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 31,440 shares of the company’s stock after purchasing an additional 10,754 shares during the period. JPMorgan Chase & Co.’s holdings in Atyr PHARMA were worth $55,000 at the end of the most recent reporting period. 61.72% of the stock is owned by institutional investors.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.